ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
ALX Oncology was founded in 2015 by Jaume Pons.
1282 health care and life sciences companies are in the directory, 519 of them in the same 11-50 employee range and 43 based in San Francisco Bay Area.
ALX Oncology may be growing as evidenced by the recent financial results and corporate developments reported for Q3 2023. The company has also been recognized by an investment firm, with abrdn plc acquiring a significant number of shares, indicating investor confidence. Furthermore, ALX Oncology has been actively advancing its clinical programs, as demonstrated by the initiation of a Phase 2 investigator-sponsored trial and the acceptance of clinical abstracts for presentation at major industry meetings, which suggests progress in its product development pipeline.
“We’re dedicated to expanding the possibilities for patients by developing novel approaches to optimize current and future standards of care.” alxoncology.com
ALX Oncology is a biopharma company based in San Francisco Bay Area, with 11-50 employees, founded in 2015. Its founder is Jaume Pons and it has raised $329.2 million over 6 rounds.
11-50 employees · acernatec.com
11-50 employees · a-biodesign.com
51-100 employees · acrivon.com
51-100 employees · 4basebio.com
1-10 employees · 101therapeutics.com
501-1,000 employees · apcerls.com
11-50 employees · 3tbiosciences.com
11-50 employees · adm-labs.com
11-50 employees · advancells.com
11-50 employees · aardvarktherapeutics.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.